Johnson & Johnson $JNJ Shares Acquired by Guinness Asset Management LTD

Guinness Asset Management LTD increased its position in shares of Johnson & Johnson (NYSE:JNJ) by 1.5% during the 2nd quarter, HoldingsChannel reports. The fund owned 1,377,201 shares of the company’s stock after acquiring an additional 20,088 shares during the quarter. Johnson & Johnson comprises approximately 3.8% of Guinness Asset Management LTD’s portfolio, making the stock its 12th biggest holding. Guinness Asset Management LTD’s holdings in Johnson & Johnson were worth $210,365,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also recently bought and sold shares of the company. Brighton Jones LLC raised its position in shares of Johnson & Johnson by 13.9% during the 4th quarter. Brighton Jones LLC now owns 51,876 shares of the company’s stock valued at $7,502,000 after buying an additional 6,332 shares during the period. Wealth Group Ltd. acquired a new stake in Johnson & Johnson during the first quarter worth $218,000. Motiv8 Investments LLC raised its position in Johnson & Johnson by 6.6% in the first quarter. Motiv8 Investments LLC now owns 9,164 shares of the company’s stock valued at $1,520,000 after purchasing an additional 564 shares during the period. PDS Planning Inc lifted its stake in shares of Johnson & Johnson by 9.3% in the 1st quarter. PDS Planning Inc now owns 18,586 shares of the company’s stock valued at $3,082,000 after purchasing an additional 1,589 shares during the last quarter. Finally, Perpetual Ltd grew its holdings in shares of Johnson & Johnson by 27.2% during the 1st quarter. Perpetual Ltd now owns 41,288 shares of the company’s stock worth $6,847,000 after purchasing an additional 8,830 shares during the period. 69.55% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity at Johnson & Johnson

In related news, EVP Jennifer L. Taubert sold 56,471 shares of the company’s stock in a transaction that occurred on Thursday, September 4th. The shares were sold at an average price of $177.81, for a total transaction of $10,041,108.51. Following the sale, the executive vice president directly owned 178,013 shares in the company, valued at approximately $31,652,491.53. This represents a 24.08% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Corporate insiders own 0.16% of the company’s stock.

Johnson & Johnson Price Performance

Johnson & Johnson stock opened at $190.38 on Monday. The company’s 50 day moving average is $182.26 and its two-hundred day moving average is $166.37. The firm has a market cap of $458.69 billion, a PE ratio of 18.38, a price-to-earnings-growth ratio of 2.24 and a beta of 0.40. The company has a quick ratio of 0.80, a current ratio of 1.07 and a debt-to-equity ratio of 0.50. Johnson & Johnson has a 52-week low of $140.68 and a 52-week high of $194.48.

Johnson & Johnson (NYSE:JNJ) last announced its quarterly earnings data on Wednesday, August 30th. The company reported $2.26 earnings per share (EPS) for the quarter. The business had revenue of $24.02 billion for the quarter. Johnson & Johnson had a return on equity of 32.73% and a net margin of 27.26%. On average, research analysts expect that Johnson & Johnson will post 10.58 EPS for the current fiscal year.

Johnson & Johnson Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 9th. Stockholders of record on Tuesday, November 25th will be paid a $1.30 dividend. This represents a $5.20 annualized dividend and a dividend yield of 2.7%. The ex-dividend date is Tuesday, November 25th. Johnson & Johnson’s dividend payout ratio (DPR) is presently 50.19%.

Wall Street Analysts Forecast Growth

A number of research firms have commented on JNJ. Wall Street Zen raised shares of Johnson & Johnson from a “hold” rating to a “buy” rating in a research report on Saturday, September 13th. UBS Group upped their price objective on shares of Johnson & Johnson from $190.00 to $214.00 and gave the stock a “buy” rating in a report on Tuesday, October 14th. Raymond James Financial lifted their target price on shares of Johnson & Johnson from $174.00 to $209.00 and gave the company an “outperform” rating in a report on Wednesday, October 15th. Wells Fargo & Company set a $212.00 price target on Johnson & Johnson and gave the stock an “overweight” rating in a research note on Friday, October 3rd. Finally, Cowen reaffirmed a “buy” rating on shares of Johnson & Johnson in a research note on Tuesday, October 14th. Three analysts have rated the stock with a Strong Buy rating, fourteen have issued a Buy rating and nine have assigned a Hold rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $199.05.

Johnson & Johnson Company Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.